- Home
- LTRN
LTRN
Lantern Pharma Inc.
as of 03-17-2026 3:59pm EST
$2.32
$0.09
-3.73%
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 31.5M | IPO Year: | 2020 |
| Target Price: | $25.00 | AVG Volume (30 days): | 45.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | -31.29 |
| 52 Week Low/High: | $2.34 - $5.74 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -2.02 | Index: | N/A |
| Free Cash Flow: | -17825796.0 | FCF Growth: | N/A |
AI-Powered LTRN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.00%
70.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 13, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 13, 2025 · 100% conf.
AI Prediction SELL
1D
-4.44%
$3.31
Act: -2.31%
5D
-11.32%
$3.07
Act: -13.29%
20D
-9.87%
$3.12
Act: +4.05%
Price: $3.46 Prob +5D: 0% AUC: 1.000
0001493152-25-022134
false 0001763950
0001763950
2025-11-13 2025-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 13, 2025
Lantern Pharma Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-39318
46-3973463
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS
Employer
Identification No.)
1920 McKinney Avenue, 7th Floor
Dallas, Texas
75201
(Address of Principal Executive Offices)
(Zip Code)
(972) 277-1136
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Common Stock
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value
LTRN
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On November 13, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
On November 13, 2025, the Company will utilize a presentation to assist with the Company’s discussions during a conference call and live webinar hosted by the Company to discuss financial and operating results for the third quarter ended September 30, 2025. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Exhibit Description
99.1
Press Release dated November 13, 2025 announcing financial results for quarter ended September 30, 2025.
99.2
Presentation relating to November 13, 2025 conference call and live webinar to discuss financial and operating results for quarter ended September 30, 2025.
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Lantern Pharma Inc.,
A Delaware Corporation
Dated: November 13, 2025 By: /s/ David R. Margrave
David R. Margrave, Chief Financial Officer
3
2025 Q2 Q2 2025 Earnings
8-K Aug 13, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 13, 2025
0001641172-25-023489
false 0001763950
0001763950
2025-08-13 2025-08-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2025
Lantern Pharma Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-39318
46-3973463
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS
Employer
Identification No.)
1920 McKinney Avenue, 7th Floor
Dallas, Texas
75201
(Address of Principal Executive Offices)
(Zip Code)
(972) 277-1136
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Common Stock
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value
LTRN
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On August 13, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Exhibit Description
99.1
Press Release dated August 13, 2025 announcing financial results for quarter ended June 30, 2025.
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Lantern Pharma Inc.,
A Delaware Corporation
Dated: August 13, 2025 By: /s/ David R. Margrave
David R. Margrave, Chief Financial Officer
3
2025 Q1 Q1 2025 Earnings
8-K May 15, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 15, 2025
0001641172-25-010541
false 0001763950
0001763950
2025-05-15 2025-05-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2025
Lantern Pharma Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-39318
46-3973463
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS
Employer
Identification No.)
1920 McKinney Avenue, 7th Floor
Dallas, Texas
75201
(Address of Principal Executive Offices)
(Zip Code)
(972) 277-1136
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Common Stock
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value
LTRN
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On May 15, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
On May 15, 2025, the Company will utilize a presentation to assist with the Company’s discussions during a conference call and live webinar hosted by the Company to discuss financial and operating results for the first quarter ended March 31, 2025. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Exhibit Description
99.1
Press Release dated May 15, 2025 announcing financial results for quarter ended March 31, 2025.
99.2
Presentation relating to May 15, 2025 conference call and live webinar to discuss financial and operating results for quarter ended March 31, 2025.
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Lantern Pharma Inc.,
A Delaware Corporation
Dated: May 15, 2025 By: /s/ David R. Margrave
David R. Margrave, Chief Financial Officer
3
Latest Lantern Pharma Inc. News
LTRN Breaking Stock News: Dive into LTRN Ticker-Specific Updates for Smart Investing
Compare LTRN vs Leading Stocks
See how LTRN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LTRN Lantern Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.